Drospiren is not active in any androgen, estrogen, glucocorticoid, or antiglucocorticoid. This property, combined with its anti-mineralocorticoid and anti-androgenic properties, makes the biochemical and pharmacological properties of drospirenone very similar to natural progesterone. In addition, there is evidence that the risk of endometrial and ovarian cancer is reduced. Moreover, higher doses of COCs (ethinyl estradiol 0.05 mg) have been shown to reduce the incidence of ovarian cysts, pelvic inflammatory disease, benign breast disease, and ectopic pregnancy.
In addition to contraception, drospirenone has other advantageous properties. Drospirenone has anti-mineralocorticoid activity and prevents weight gain and other symptoms caused by fluid retention. It fights estrogen-related sodium retention, provides good tolerance, and has a positive effect on premenstrual syndrome (PMS). The world's number one short-acting oral contraceptive, Yosmine, has the most advanced and closest natural progesterone, drospirenone, which provides very reliable contraceptive effects without increasing body weight and positive effect for acne.
White or almost white crystalline powder
Limit of 1,2-dimethoxyethane
Limit of isopropyl ether
Related substances (HPLC)
Single impurity NMT 0.1%
Total impurities NMT 0.4%
Conclusion: It conforms to the USP32 STANDARD.